Glucotrack, Inc. is set to be delisted from Nasdaq after failing to meet the minimum bid price requirement. The company received a determination from Nasdaq on October 28, 2026, stating that its closing bid price was below $1.00, a violation of Nasdaq Listing Rule 5550(a)(2). This delisting is significant as it affects Glucotrack's visibility and trading options in the market.

Glucotrack, Inc., identified by the ticker GCTK, operates within the surgical and medical instruments and apparatus sector. The company has been navigating challenges in maintaining its stock price, which is critical for compliance with Nasdaq's listing standards. The recent filing reveals that the company's stock closed at $0.87 on October 14, 2026, prompting the delisting decision.

According to the filing, the Nasdaq Hearings Panel had previously granted Glucotrack an exception to regain compliance, contingent on maintaining a closing bid price of at least $1.00 through November 9, 2026. However, the company's inability to meet this requirement has led to the current situation. The filing states, "Trading in the Company’s common stock on Nasdaq will be suspended at the open of trading on October 30, 2026." Additionally, Glucotrack expects Nasdaq to file a Form 25 to officially delist its securities.

In light of the delisting, Glucotrack plans to have its shares quoted by the OTC Markets Group, Inc. The company intends to submit an application for its securities to be traded on the OTCID Market. This transition to over-the-counter trading may provide Glucotrack with continued access to capital markets, albeit with potentially reduced visibility compared to its previous Nasdaq listing.

The impact of this delisting extends beyond Glucotrack itself. It may influence investor confidence and market perceptions of companies within the surgical and medical instruments sector. As Glucotrack navigates this transition, it will be crucial for the company to communicate its strategies to regain compliance and reassure stakeholders.

Looking ahead, Glucotrack has not specified the next steps beyond its application for OTC trading. The company will need to focus on strategies to improve its stock price and regain compliance with listing standards to enhance its market position.